法洛四联症跨环补片术后人工瓣膜远期耐久性研究
该单中心回顾性研究纳入211例因法洛四联症跨环补片术后行肺动脉位置生物瓣或带瓣管道置入的患者,共255次手术。首次肺动脉瓣置换中位年龄15.4岁,5、10、15年免于再干预率分别为94%、77%、64%。多变量分析显示年轻年龄、较小瓣膜尺寸和男性与再干预风险更高独立相关,同种移植物与异种移植物免于再干预无差异(P=0.938),经皮瓣膜平均耐久性9.4年显著低于其他人工瓣膜(P=0.007)。
要点
- 年轻年龄和较小瓣膜尺寸与生物瓣耐久性降低相关。
- 同种移植物与异种移植物免于再干预无显著差异(P=0.938)。
- 经皮瓣膜平均耐久性9.4年,显著低于其他人工瓣膜(P=0.007)。
核心结论
- 年轻患者年龄和较小瓣膜尺寸与生物瓣耐久性降低相关。
- 需关注青少年期早期行肺动脉瓣置换以整体保护右心室功能。
研究设计与样本
- 单中心回顾性研究,纳入法洛四联症跨环补片术后行生物瓣或带瓣管道置入的患者。
- 共211例患者、255次手术,首次肺动脉瓣置换中位年龄15.4岁(IQR 12.3-20.7岁)。
- 主要终点为免于肺动脉瓣置换再干预,复合次要终点为免于再干预和结构性瓣膜退化。
主要发现
- 5、10、15年免于再干预率分别为94%、77%、64%。
- 多变量分析显示年轻年龄、较小瓣膜尺寸和男性与再干预风险更高独立相关。
- 植入瓣膜中生物瓣122个,同种移植物38个(18%),经皮瓣膜37个(17%),其他人工瓣膜或管道14个(7%)。
- 同种移植物与所有其他异种移植物免于再干预无差异(P=0.938)。
- 经皮瓣膜平均耐久性9.4年,显著低于其他人工瓣膜(P=0.007)。
临床怎么用
- 对法洛四联症跨环补片术后需肺动脉瓣置换的年轻、小瓣膜尺寸患者,应预期生物瓣耐久性较低并加强随访。
- 选择瓣膜类型时需权衡经皮瓣膜耐久性较短(平均9.4年)与其他瓣膜的再干预风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to determine the longevity of bioprosthetic valves (BPVs) or valved conduits in the pulmonary position and the factors associated with prosthetic valve longevity in patients who underwent surgical repair of tetralogy of Fallot (TOF). METHODS: We performed a single-centre retrospective study in patients undergoing placement of a bioprosthesis or valved conduit in patients operated for TOF with a transannular patch. The primary end-point was freedom from pulmonary valve replacement (PVR) reintervention. The composite secondary end-point was freedom from PVR reintervention and structural valve degeneration. RESULTS: A total of 211 patients undergoing 255 operations were identified. The median age at first PVR was 15.4 years (IQR 12.3-20.7 years). The freedom from reintervention at 5, 10, and 15 years was 94%, 77%, and 64%, respectively. Multivariable analysis shows that factors that are independently associated with a more significant hazard of reintervention are younger age, smaller valve size, and male sex. Of the implanted prosthetic valves, 122 were bioprosthesis; 38 (18%) were homografts; 37 (17%) percutaneous valve, and 14 (7%) were other prosthetic valves or conduits. The freedom from reintervention was not different between homografts and all other heterografts (P = 0.938). Percutaneous valves showed an average longevity of 9.4 years, significantly lower than other prosthetic valves (P = 0.007). CONCLUSIONS: Younger patient age and a smaller valve size were associated with reduced BPV durability. There is a concern about an early PVR to preserve right ventricle function overall during adolescent age.
引用
- Brancaccio G, Verrengia M, Trezzi M, et al. Investigating the Long-term Durability of Prosthetic Valves in Patients Who Have Undergone Tetralogy of Fallot Surgery with Transannular Patch. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40613688. doi:10.1093/icvts/ivaf159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。